Skip to main content

melanoma Archives

Entertainers’ support strengthens VICC melanoma research efforts

Apr. 12, 2018—Henry Paul and Dave Robbins, members of country music group BlackHawk, as well as southern rock band The Outlaws, recently donated $40,000 to Vanderbilt-Ingram Cancer Center (VICC) in support of melanoma research. Since 2006, the band members have generated more than $100,000 for VICC.

Read more


“Idling” cancer cells may return

Apr. 11, 2018—Vanderbilt investigators have discovered that cancer treatment induces an “idling” state for cells, which could promote resistance to treatment.

Read more


STINGing combination for cancer

Jun. 19, 2017—A novel immunotherapy combination induced remarkable regression of tumors in a mouse model of head and neck cancer.

Read more


Melanoma study finds new way to enhance targeted therapies

Mar. 9, 2017—With the help of a drug formerly used to treat HIV/AIDS, researchers at Vanderbilt University Medical Center (VUMC) have found a way to make melanoma cells more vulnerable to targeted anti-cancer therapy.

Read more


Melanoma response to immune therapy

Mar. 3, 2016—Melanoma-specific expression of a certain protein identifies tumors that are more responsive to an immune therapy.

Read more


Combining treatments for melanoma

Feb. 18, 2016—Combining therapies for melanoma that induce cell senescence and that activate the immune response may improve outcomes for patients.

Read more


Investigators find clues to melanoma treatment resistance

Oct. 29, 2015—Nearly half of all patients with malignant melanoma, the most deadly form of skin cancer, have a mutation in the BRAF gene found in their tumors. Mutations in the BRAF gene turn on a cancer growth switch known as the MAP kinase pathway.

Read more


Gene mutations may predict melanoma response to immunotherapies

Mar. 12, 2015—Melanoma patients whose tumors test positive for mutations in the NRAS gene were more likely to benefit from new immunotherapy drugs, according to a new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators.

Read more


Study tracks combination therapy to treat melanoma

Jan. 8, 2015—Melanoma is the most lethal form of skin cancer, with high mortality rates. While new drugs have been approved to treat the disease, patients nearly always develop resistance to the therapies and the cancer advances.

Read more


Immune cell activity and melanoma

Nov. 6, 2014—The activity of a certain factor in immune cells is essential for an anti-tumor response, emphasizing the need to consider the effects of anti-cancer therapies on immune cells.

Read more


Indiana couple hits the links to support melanoma research

Oct. 16, 2014—A Vanderbilt-Ingram Cancer Center (VICC) melanoma patient is using his passion for golf to support melanoma research efforts at VICC.

Read more


VICC researchers in spotlight at national cancer conference

Jun. 19, 2014—New Vanderbilt research suggests patients with advanced melanoma — the most deadly form of skin cancer — could safely benefit from a combination of immunotherapy and targeted therapies aimed at specific gene mutations.

Read more


Page 1 of 212

Recent Stories from VUMC News and Communications Publications

Our amazing skin

Vanderbilt Medicine

Our amazing skin

Biology and the beat

Vanderbilt Medicine

Biology and the beat

Community care

Vanderbilt Nurse

Community care

Survive and thrive

Hope

Survive and thrive

more